Free Trial Information
BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

...of semaglutide to treat Type II diabetes. The agency requested additional information relating to the GLP-1...
Read More
BioCentury | Mar 5, 2021
Product Development

Lilly’s tirzepatide more potent than Novo’s semaglutide, but higher discontinuation: Data Byte

...and 15 mg doses of tirzepatide, a GIP and GLP-R1 co-agonist, with 1 mg of GLP-R1...
...study drug or initiating rescue therapy for persistent severe hyperglycemia. TARGETSGIP - Gastric inhibitory protein GLP-1R...
...Compound #), subcutaneous semaglutide (Informal) Eli Lilly and Co. Novo Nordisk A/S Gastric inhibitory protein (GIP) Glucagon-like peptide-1 receptor (GLP-1R...
Read More
BioCentury | Feb 18, 2021
Regulation

Feb. 18 Quick Takes: Label expansion for Entresto; plus Amgen, Sesen, BeiGene, Cortexyme and more

...and 40 weeks, respectively. Data from the Phase III SURPASS-2 trial comparing the GIP and GLP-1...
Read More
BioCentury | Jan 23, 2021
Translation in Brief

Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

Ionis’ antisense oligonucleotide therapy prevents malignant myeloma regenerationUniversity of California San Diego and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) researchers described in Cell Stem Cell an IRF4 antisense oligonucleotide (ASO), ION251, that reduced tumor growth, impaired myeloma progenitor regeneration and...
Read More
BioCentury | Dec 30, 2020
Distillery Therapeutics

Targeting the histone methyltransferase EHMT2 for breast cancer recurrence

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting the histone methyltransferase EHMT2 could treat recurrent breast cancer. In murine recurrent breast cancer cell lines, EHMT2 knockout or treatment with an EHMT2 inhibitor tool compound decreased proliferation. The tool...
Read More
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...Alzheimer’s disease. The biological rationale for testing a GLP-1...
...becomes less sensitive to insulin in Alzheimer's and GLP-1...
...brain, suggesting it could be neuroprotective. Third, GLP-1s...
Read More
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

...the Phase III SURPASS-1 trial to treat adults with Type II diabetes. The co-agonist of GLP-1...
Read More
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

...Nov. 10, Neuraly announced a sponsored research agreement with the Penn team to study the GLP-1R...
...Parkinson’s.Eli Lilly and Co. (NYSE:LLY) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) market Trulicity dulaglutide, a long-acting GLP-1R...
...diabetes.GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) markets Eperzan albiglutide, a GLP-1R agonist comprising 2 copies of modified human GLP-1...
Read More
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...Zhongxin Capital and Harvest Capital participated in the financing. The company has advanced its lead GLP-1R...
Read More
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...of Ozempic in the Phase IIIb SUSTAIN FORTE trial. The higher dose of the once-weekly GLP-1...
Read More
Items per page:
1 - 10 of 1324